Century Therapeutics, Inc.
IPSC
$2.44
$0.146.09%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 109.16M | 113.34M | 114.13M | 114.90M | 6.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 109.16M | 113.34M | 114.13M | 114.90M | 6.59M |
| Cost of Revenue | 95.66M | 105.34M | 110.04M | 110.40M | 107.24M |
| Gross Profit | 13.50M | 8.00M | 4.09M | 4.50M | -100.65M |
| SG&A Expenses | 28.92M | 31.05M | 32.57M | 33.07M | 33.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 124.58M | 136.39M | 142.61M | 143.47M | 140.65M |
| Operating Income | -15.42M | -23.05M | -28.48M | -28.57M | -134.06M |
| Income Before Tax | -9.64M | -24.70M | -21.51M | -20.16M | -124.78M |
| Income Tax Expenses | -68.00K | 1.78M | 1.77M | 1.79M | 1.79M |
| Earnings from Continuing Operations | -9.57 | -26.48 | -23.28 | -21.95 | -126.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.57M | -26.48M | -23.28M | -21.95M | -126.57M |
| EBIT | -15.42M | -23.05M | -28.48M | -28.57M | -134.06M |
| EBITDA | -2.32M | -10.18M | -15.44M | -15.27M | -120.75M |
| EPS Basic | -0.11 | -0.31 | -0.28 | -0.28 | -1.62 |
| Normalized Basic EPS | -0.05 | -0.10 | -0.13 | -0.13 | -0.97 |
| EPS Diluted | -0.11 | -0.32 | -0.29 | -0.29 | -1.63 |
| Normalized Diluted EPS | -0.05 | -0.10 | -0.13 | -0.13 | -0.97 |
| Average Basic Shares Outstanding | 346.01M | 344.14M | 342.38M | 338.23M | 314.51M |
| Average Diluted Shares Outstanding | 346.09M | 344.21M | 342.45M | 338.31M | 314.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |